Focus: Bio-Path Holdings is a public biotechnology company specializing in antisense DNA therapeutics, with a focus on gene therapy applications in hematologic malignancies and solid tumors.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Bio-Path Holdings to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bio-Path Holdings
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bio-Path Holdings's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Bio-Path Holdings, Inc. Announces Domestication to Wyoming and Amendment Creating Series S Preferred Stock - Minichart
Bio-Path Holdings, Inc. Announces Domestication to Wyoming and Amendment Creating Series S Preferred Stock Minichart
8-K Filing: BIO-PATH HOLDINGS, INC. (BPTH) (CIK 0001133818) — FORM 8-K
FORM 8-K
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 6 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo